Allt inom Interim
Nanexa publishes interim report for January – March 2023
Positive pre-clinical data with NEX-22, NEX-20 phase I continues and good progress in partner projects
Nanexa publishes year-end report for 2022
Agreement and directed issue to Novo Nordisk, solution to patent infringement lawsuit and phase 1 study with NEX-20 started